CDT Equity shares are trading lower. The company announced a partnership with QIMA Life Sciences to explore the potential of several of CDT’s assets in autoimmune skin diseases.

Benzinga Newsdesk www.benzinga.com Positive 50.3%

Neg 0% Neu 0% Pos 50.3%

Comments

No comments yet. Be the first!